uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update ~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease; PDUFA target action date of May 1, 2027 ~ ~ Aligned with FDA on key elements of c

Event · Earnings
Original reporting
Published Nov 4, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$QURE
Bullish
high confidence
Mentioned
$QURE
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QUREBullishHigh
01

Why it matters

The priority review and cash runway provide near‑term upside, but execution risk remains for later‑stage trials.

02

Market read

Primary biotech news with material regulatory and financial data; actionable for traders.

03

What to watch

High cash burn and upcoming large trial costs could pressure liquidity if milestones slip.

Relevance 8/10Novelty 8/10Timing: pre‑market today
AlphAI · Earnings readQURE · Third quarter of 2026 · ended September 30, 2026

uniQure reported third-quarter 2026 revenue of $5.2 million and a net loss of $61.2 million while the FDA granted Priority Review to the AMT-130 BLA, with a PDUFA target action date of May 1, 2027.

→Mixed quarter

Revenue increased to $5.2 million and net loss narrowed to $61.2 million, while cash, cash equivalents and investment securities rose to $768.4 million and are expected to fund projected operating expenses into 2030. The operating update is centered on Priority Review for AMT-130, but operating expenses increased and the BLA remains subject to FDA review and a planned confirmatory study.

Revenue
$5.2M
increase of $1.5 million y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, three months ended September 30, 2026GAAP$5.2M–increase of $1.5 million
Cost of license revenues, three months ended September 30, 2026GAAP−$236K––
Research and development expenses, three months ended September 30, 2026GAAP$35.5M–$1.1 million increase
Selling, general and administrative expenses, three months ended September 30, 2026GAAP$23.9M–$4.5 million increase
Total operating expenses, three months ended September 30, 2026GAAP−$59.67M––
Other income, three months ended September 30, 2026GAAP$1.69M––
Other expense, three months ended September 30, 2026GAAP−$195K––
Loss from operations, three months ended September 30, 2026GAAP−$52.98M––
Non-operating items, net, three months ended September 30, 2026GAAPexpense of $7.6 million–$13.3 million decrease in net non-operating expense
Loss before income tax expense, three months ended September 30, 2026GAAP−$60.54M––
Income tax expense, three months ended September 30, 2026GAAP−$676K––
Net loss, three months ended September 30, 2026GAAP$61.2M––
Basic and diluted net loss per ordinary share, three months ended September 30, 2026GAAP$0.88 basic and diluted loss per ordinary share––
Weighted average shares used in computing basic and diluted net loss per ordinary share, three months ended September 30, 2026GAAP69,900,863––
Cash, cash equivalents and investment securities, September 30, 2026GAAP$768.4M––
Long-term debt, September 30, 2026GAAP$50.34M––
Liability from royalty financing agreement, September 30, 2026GAAP$497.3M––
Total assets, September 30, 2026GAAP$940.6M––
Total liabilities, September 30, 2026GAAP$645.9M––
Total shareholders' equity, September 30, 2026GAAP$294.7M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Projected operating expenses into 2030 outlook

  • NoteThe Company expects that these resources will be sufficient to fund projected operating expenses into 2030.
  • NotePDUFA target action date of May 1, 2027.
  • NoteThe Company plans to initiate patient screening, beginning in the U.S., by the end of 2026.
  • NoteThe Company expects to present updated results in the first half of 2027.

What drove it

  • Revenue increased by $1.5 million due to an increase in license revenue compared to the prior period.
  • Research and development expense increased primarily from a $3.6 million increase in employee and contractor-related expenses including share-based compensation, partially offset by a $2.3 million decrease in direct research and development expenses.
  • The decrease in direct research and development expenses reflected a $4.1 million reduction in process validation expenses related to ifezuntirgene inilparvovec, partly offset by a $1.5 million increase in expenses related to AMT-260 and a $1.7 million increase in expenses related to preclinical activities and technology innovation projects.
  • Selling, general and administrative expense increased primarily from a $3.0 million increase in employee and contractor-related expenses, including share-based compensation, a $0.7 million increase in professional fees and a $0.7 million increase in information technology costs to support potential commercial launches of ifezuntirgene inilparvovec.
  • The decrease in net non-operating expense was primarily due to a $6.3 million reduction of expenses related to pre-funded warrants and a $6.8 million improvement of net interest income.
  • The FDA accepted the AMT-130 BLA under the Accelerated Approval pathway and granted Priority Review, with a PDUFA target action date of May 1, 2027.

Concerns

  • The BLA is supported by 36-month data from 12 high-dose patients compared with a propensity score-matched external control.
  • At 48 months, cUHDRS showed a 44% slowing of disease progression versus the updated external control, with non-significant p=0.144.
  • AMT-191 dosing had previously been paused after asymptomatic liver enzyme elevations in two mid-dose patients, which resolved following a course of immunosuppression.
  • The FDA may ultimately conclude that the Phase I/II trial data for ifezuntirgene inilparvovec are not sufficient to support approval, according to the company's forward-looking statements.

What to watch

  • FDA action on the AMT-130 BLA by the PDUFA target action date of May 1, 2027.
  • Initiation of U.S. patient screening for the AMT-130 confirmatory study by the end of 2026.
  • The approximately 200-patient AMT-130 confirmatory study, randomized in a 2:1 ratio to treatment or standard of care, with TFC as the primary endpoint at 36 months.
  • Updated Phase I/IIa results for AMT-260 and updated Phase I/II results across all AMT-191 dosing cohorts, both expected in the first half of 2027.
  • Progress in building field medical, market access and strategic account teams ahead of a potential AMT-130 launch.

Balance sheet and cash flow

  • Cash and cash equivalents: $ 98,442 as of September 30, 2026, compared to $ 80,240 as of December 31, 2025.
  • Current investment securities: $ 570,021 as of September 30, 2026, compared to $ 542,301 as of December 31, 2025.
  • Non-current investment securities: $ 99,967 as of September 30, 2026, compared to - as of December 31, 2025.
  • Other investments: $ 31,539 as of September 30, 2026, compared to $ 30,237 as of December 31, 2025.
  • Total current assets: $ 692,545 as of September 30, 2026, compared to $ 655,986 as of December 31, 2025.
  • Total non-current assets: $ 248,006 as of September 30, 2026, compared to $ 168,922 as of December 31, 2025.
  • Accounts payable: $ 6,173 as of September 30, 2026, compared to $ 5,170 as of December 31, 2025.
  • Accrued expenses and other current liabilities: $ 50,979 as of September 30, 2026, compared to $ 41,292 as of December 31, 2025.
  • Liability related to pre-funded warrants: - as of September 30, 2026, compared to $ 12,595 as of December 31, 2025.
  • Total current liabilities: $ 60,142 as of September 30, 2026, compared to $ 62,919 as of December 31, 2025.
  • Total non-current liabilities: $ 585,756 as of September 30, 2026, compared to $ 563,088 as of December 31, 2025.
  • No operating cash flow or free cash flow was reported.

Analysis

Third-quarter revenue was $5.2 million, compared with $3.7 million in the same period in 2025. The company attributed the $1.5 million increase to higher license revenue. The business remained loss-making, with a $61.2 million net loss and $0.88 basic and diluted loss per ordinary share, compared with a $80.5 million net loss and $1.38 basic and diluted loss per ordinary share in the comparative period.

Operating expense increased year over year. Research and development expense was $35.5 million versus $34.4 million, as higher employee and contractor-related costs including share-based compensation were partly offset by lower direct research and development expense. Selling, general and administrative expense was $23.9 million versus $19.4 million, driven by recruitment, professional fees and information technology costs supporting potential commercial launches. Non-operating expense improved by $13.3 million, principally from lower pre-funded-warrant expense and improved net interest income.

The primary operating catalyst is AMT-130 in Huntington’s disease. The FDA accepted the BLA submitted under the Accelerated Approval pathway, granted Priority Review, and set a May 1, 2027 PDUFA target action date. The company also aligned with the FDA on a confirmatory study designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 patients, with TFC as the primary endpoint at 36 months. U.S. patient screening is planned by the end of 2026.

Clinical evidence cited for AMT-130 includes 36-month data from 12 high-dose patients supporting the BLA and updated analyses from the Phase I/II program. The 48-month cUHDRS result in 12 high-dose patients showed a 44% slowing versus the updated external control with non-significant p=0.144, while TFC showed a 61% slowing with nominal p=0.008. The company reported $768.4 million of cash, cash equivalents and investment securities as of September 30, 2026 and expects these resources to fund projected operating expenses into 2030. The filing reported no operating cash flow, free cash flow, repurchases or dividends.

Management, verbatim

Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and families living with Huntington’s disease.

Matthew Kapusta, chief executive officer at uniQure

We strongly believe AMT-130 has the potential to deliver meaningful benefit to HD patients. With our BLA under Priority Review and preparations for the confirmatory study underway, we are committed to bringing this therapy to patients and families who continue to live with this devastating disease.

Matthew Kapusta, chief executive officer at uniQure

As we continue to build our commercial capabilities and prepare for a potential launch, we are energized by what lies ahead, and our financial strength provides us the runway to deliver on our plans.

Matthew Kapusta, chief executive officer at uniQure

Not in the filing

stated, not guessed
  • Gross margin was not reported.
  • Segment revenue was not reported.
  • Non-GAAP revenue, earnings, operating income, net income, EPS or other non-GAAP financial measures were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Prior-quarter comparisons were not reported.
  • A revenue, gross margin, operating expense or tax-rate guidance range was not reported.
  • CFO commentary was not provided.
  • The previous outlook covered funding into 2030 and regulatory and clinical milestones only, with no numeric guidance for the third quarter of 2026 results, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

QURE filed a Form 8‑K announcing Q3 2026 financials and regulatory updates for its Huntington's disease program.

Company-level read

Ticker impact

$QUREBullishHigh confidence
Context

SEC 8‑K reports QURE's Q3 2026 results, cash balance of $768.4 M and FDA priority review of its Huntington's disease gene therapy.

Expected impact

likely upward pressure as market prices in the priority review and extended runway

Evidence & confidence

FDA priority review is a material catalyst for a biotech; cash runway reduces financing risk.

Market effects

May boost sentiment for gene‑therapy and biotech sector peers.

Positive for US biotech listings; limited broader market effect.

Highlights continued FDA focus on rare‑disease therapies.

Counterpoint

If the confirmatory trial fails to meet endpoints, the stock could face sharp downside.

Key entities

  • uniQure N.V.

    NASDAQ‑listed gene‑therapy developer.

  • FDA

    U.S. Food and Drug Administration granting priority review.

Every QURE earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$QUREMedAI 8/10

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure N.V. (QURE) shares rose 17.5% in a month, outperforming the industry and S&P 500. The rally was driven by FDA acceptance of its Huntington's disease drug application, ifezuntirgene inilparvovec, for review. Despite weaker Q3 2026 results, investors focus on the drug's potential. QURE's cash position is strong, with $768.4M as of Sept. 30, 2026, expected to fund operations through 2030.

$QUREMedAI 8/10

uniQure Prepares for Potential FDA Panel on Huntington’s Gene Therapy After Priority Review Nod

uniQure (QURE) is preparing for a potential FDA panel review of its gene therapy AMT-130 for Huntington's disease after receiving a priority review nod. The company presented 48-month data showing treated patients had less functional decline than untreated ones, though control group limitations were noted. uniQure plans a confirmatory study and is preparing for a potential launch, with $780 million in cash to fund operations into 2030.

$QUREHighAI 9/10

Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40%

uniQure's AMT-130 was accepted for FDA Priority Review with a decision goal of May 1, 2027. The U.K. validated its marketing application. 48-month data showed slowed Huntington’s disease progression. Q3 2026 revenue rose 40.4% to $5.2 million, below estimates, with net loss narrowing to $61.2 million. Cash reserves were $768.4 million.

MedAI 8/10

uniQure N.V. Q3 2026 Earnings Call Summary

uniQure N.V. reported that the FDA accepted its AMT-130 BLA with priority review for Huntington's disease, citing 36-month data showing a 60% slowing in TFC decline. The company plans a focused commercial launch targeting 15-30 priority institutions. Management expects the confirmatory study to be underway by the 2027 PDUFA date and cash runway to extend into 2030. SG&A expenses increased by $4.5 million year-over-year.

$QUREMed

uniQure (QURE) Q3 2026 Earnings Call Transcript

uniQure (QURE) reported progress in its Q3 2026 earnings call. The company's AMT-130 therapy for Huntington's disease showed a 75% slowing of disease progression in trials. The FDA is reviewing the Biologics License Application (BLA) with a PDUFA date of May 1, 2027. uniQure is preparing for a potential U.S. launch in 2027 and advancing its pipeline, including studies for AMT-260 and AMT-191. The company is also building its commercial teams ahead of the planned launch.